Patient demographic and clinical characteristics
| Betaferon (n=29) | Avonex (n=44) | Rebif (n=52) | |
|---|---|---|---|
| EDSS, expanded disability status scale. | |||
| Sex | |||
| Male | 9 | 14 | 13 |
| Female | 20 | 30 | 39 |
| Age (years) | |||
| Mean (SD) | 35.5 (10.8) | 35.2 (9.9) | 39.3 (10.4) |
| Range | 21–62 | 19–60 | 17–64 |
| EDSS score | |||
| Mean (SD) | 2.4 (1.3) | 1.2 (0.8) | 2.2 (1.1) |
| Range | 0–5.5 | 0–3.5 | 1–4.5 |
| Disease duration (years) | |||
| Mean (SD) | 7.8 (6.2) | 8.0 (7.8) | 7.8 (7.2) |
| Range | 0.5–22 | 0.5–40 | 0.08–24 |
| Treatment duration (months) | |||
| Mean (SD) | 15.4 (4.2) | 14.8 (4.3) | 15.0 (4.4) |
| Range | 6–18 | 6–18 | 6–18 |